Monopar Therapeutics Inc. MNPR
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- +9.37%
- 1 year
- -11.57%
- Market cap
- 479.38M
- EPS (ttm)
- -2.20
- Shares out
- 5.28M
- Forward P/E
- -10.17
- YTD return
- +9.37%
- 1-year return
- -11.57%
- Volume
- 94.21K
- Avg volume
- 164.60K
- Open
- 68.02
- Previous close
- 67.22
- Day's range
- 67.45 – 72.25
- 52-week range
- 50.07 – 124.82
- Beta
- 1.10
- Price target
- 27.33 (-61.7%)
- Earnings date
- Aug 9, 2024
5D -0.59 (-0.85%)
Key statistics
- Enterprise value
- 48.26M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 12.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.43M
- Total cash
- 7.12M
- Total debt
- 0
- Return on equity
- -102.31%
- Short % of float
- 10.22%
- 50-day average
- 17.85
- 200-day average
- 7.12
Analyst view
- Target (low)
- 22.00
- Target (mean)
- 27.33
- Target (high)
- 37.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.42.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.46 | -0.37 | +0.09 | +19.57% |
| Aug 9, 2024 | Jun 1, 2024 | -0.45 | -0.50 | -0.05 | -11.11% |
| Aug 9, 2024 | Jun 1, 2024 | -0.45 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.85 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.85 | -0.50 | +0.35 | +41.18% |
| Mar 28, 2024 | Dec 1, 2023 | -0.85 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 11, 2024 | JonesTrading | up | Hold | Buy |
| Jun 1, 2023 | HC Wainwright & Co. | reit | — | Buy |
| May 15, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- monopartx.com
News
Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data 
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145 
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday 
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128 
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119 - BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
- Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125 - Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease
Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson Disease
Your note
Sign in to keep a note on MNPR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON RAYMOND WILLIAM | Director | Conversion of Exercise of derivative security | Dec 28, 2023 | 26,863 |
| BROWN MICHAEL J | Director | Conversion of Exercise of derivative security | Dec 28, 2023 | 4,513,800 |
| CITTADINE ANDREW | Chief Operating Officer | Conversion of Exercise of derivative security | Jun 27, 2024 | 193,065 |
| KLAUSNER ARTHUR J | Director | Conversion of Exercise of derivative security | Dec 28, 2023 | 3,086,260 |
| LEO KARL | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 17, 2019 | 0 |
| MAZAR ANDREW PAUL | Officer and Director | Conversion of Exercise of derivative security | Mar 30, 2022 | 4,300,060 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.27% | 14,066 | 337.58K | Sep 29, 2024 |
| Wells Fargo & Company | 0.01% | 500 | 12.00K | Sep 29, 2024 |
| NewEdge Advisors, LLC | 0.01% | 600 | 14.40K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 512 | 12.29K | Sep 29, 2024 |
| Federation Des Caisses Desjardins Du Quebec | 0.00% | 16 | 384 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 13 | 312 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.17% | 9,034 | 216.82K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.17% | 9,024 | 216.58K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 5,241 | 125.78K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 2,621 | 62.90K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 2,690 | 64.56K | Oct 30, 2024 |